Supernus Pharmaceuticals (SUPN) versus NOVAN INC (NOVN) Head to Head Analysis

Supernus Pharmaceuticals (NASDAQ: SUPN) and NOVAN INC (NASDAQ:NOVN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Supernus Pharmaceuticals and NOVAN INC, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Supernus Pharmaceuticals 0 3 3 0 2.50
NOVAN INC 0 1 3 0 2.75

Supernus Pharmaceuticals currently has a consensus target price of $48.17, indicating a potential upside of 31.07%. NOVAN INC has a consensus target price of $17.24, indicating a potential upside of 203.57%. Given NOVAN INC’s stronger consensus rating and higher probable upside, analysts plainly believe NOVAN INC is more favorable than Supernus Pharmaceuticals.

Valuation and Earnings

This table compares Supernus Pharmaceuticals and NOVAN INC’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Supernus Pharmaceuticals $252.59 million 7.38 $82.36 million $1.95 18.85
NOVAN INC $768,999.00 118.06 -$49.04 million ($7.93) -0.72

Supernus Pharmaceuticals has higher revenue and earnings than NOVAN INC. NOVAN INC is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Supernus Pharmaceuticals and NOVAN INC’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Supernus Pharmaceuticals 41.10% 30.73% 19.48%
NOVAN INC N/A -194.61% -99.61%

Insider & Institutional Ownership

95.4% of Supernus Pharmaceuticals shares are owned by institutional investors. Comparatively, 6.1% of NOVAN INC shares are owned by institutional investors. 6.7% of Supernus Pharmaceuticals shares are owned by company insiders. Comparatively, 10.7% of NOVAN INC shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Supernus Pharmaceuticals beats NOVAN INC on 7 of the 11 factors compared between the two stocks.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In addition, it is developing multiple product candidates in psychiatry to address unmet medical needs and market opportunities for the treatment of impulsive aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). It is developing SPN-810 (molindone hydrochloride) to treat IA in patients having ADHD. It is developing SPN-812 (viloxazine hydrochloride) as a candidate to treat patients having ADHD. The Company’s neurology portfolio consists of Oxtellar XR and Trokendi XR, which are the first once-daily extended release oxcarbazepine and topiramate products, respectively, indicated for epilepsy in the United States market.

NOVAN INC Company Profile

Novan, Inc. is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs). The Company’s formulation science enables it to further tune the release of nitric oxide when applied to the skin by using the combinations of inactive ingredients. It is developing SB204 for the treatment of acne vulgaris in Phase III. The Company is developing its product candidate, SB206, for the treatment of external genital and perianal warts in Phase II. It is developing SB208, an investigational topical anti-fungal for the treatment of fungal infections of the skin and nails. It is developing SB204 for the treatment of inflammatory skin diseases. Its pipeline also includes SB414, a topical cream product candidate.

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply